Previous Close | 3.0000 |
Open | 3.0200 |
Bid | 2.8200 x 100 |
Ask | 2.9100 x 100 |
Day's Range | 2.8500 - 3.1500 |
52 Week Range | 2.8500 - 20.4000 |
Volume | |
Avg. Volume | 238,504 |
Market Cap | 74.436M |
Beta (5Y Monthly) | 1.26 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -122.5200 |
Earnings Date | Nov 12, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
The genetic testing firm will also close its therapeutics arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the long-term success of our core consumer business.”
Despite a revenue decline, 23andMe Holding Co (ME) focuses on cost-saving measures and recurring revenue growth to enhance financial stability.